ERBB2 and neoplasm: In vivo, sabizabulin proved effective in inhibiting HER2+ primary tumor growth, demonstrating higher potency than paclitaxel in BT474 xenografts, but with reduced efficacy relative to paclitaxel in the metastatic HCI-12 HER2+ PDX model.